FlexCat™ by Unifrax Produces Increased Yield with Less Coking in Model PDH Study
27.7.2021 14:00:00 EEST | Business Wire | Press release
Unifrax, a leading manufacturer of high-performance specialty materials, today announced initial results of the first phase of its testing campaign, performed at hte GmbH, leading provider of high throughput technology in catalysis research. These results support the ability of the recently launched FlexCat™ by Unifrax to significantly improve production throughput, increase process runtime and reduce a company’s carbon footprint.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005241/en/
FlexCat™ by Unifrax PDH testing results in partnership with hte GmbH. (Graphic: Business Wire)
FlexCat, a new customizable fiber-based catalyst support material, is designed for use in industrial catalysis, improving the output of hydrogen and specialty gas production, chemical processing, air purification and other chemical manufacturing applications.
Tested by hte GmbH, Unifrax targeted a model reaction of propane dehydrogenation (PDH) as a common industrial process and compared FlexCat to a literature derived and pellet-supported catalyst. Unifrax’s first step into industrial catalysis is a catalyst support material that has been proven to:
Provide enhanced yield and selectivity.
- FlexCat increased output by 20 percent in the initial cycle and retained at least 90 percent conversion activity during the subsequent cycle tested.
- This patented technology provided more tortuosity, maximizing catalyst interaction and producing 50 percent less side products per cycle, including four times less benzene.
Reduce production downtime.
- FlexCat retained its conversion activity throughout the two cycles, offering up to 50 percent reduction in regeneration time and up to 12 percent longer run time.
- FlexCat’s innovative product forms can be up to 10 times lighter than the conventional support being used, reducing loading and unloading time.
Allow for reduced downstream processing and cleaner outputs through plant optimization.
- First lab scale data showed the potential of FlexCat to significantly reduce coking, improve conversion, and increase selectivity; addressing emissions concerns and providing a safer environment for employees and surrounding communities.
“In this latest round of testing, we homed in on specific areas where our industry partners strive to see improvements and derive value – from increased yield, reduced emissions and lower carbon footprints,” said Chad Cannan, senior vice president of research and development, Unifrax. “This next generation of catalysis technology will significantly increase production through existing assets and avoid costly capital expenditures and unnecessary downtime. This data shows that companies can realize greater value through their current production systems and improve their environmental footprint.”
“This collection of data, in partnership with hte GmbH, is a step in the right direction for industrial catalysis,” said John Dandolph, president and CEO, Unifrax. “With FlexCat, we’re working to optimize plant performance and the impact on local communities, focusing on a unique, game-changing solution. In confirming that we can increase output while reducing emissions and overall costs for our industry partners, we are excited to move forward with implementing this new technology to create better and more efficient catalysis that this industry has never seen before.”
With a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, Unifrax has a deep history of fiber-based technology and manufacturing. As a first step into industrial catalysis for Unifrax, FlexCat offers a revolutionary fiber-based catalytic media that delivers more than the alumina-based catalysis technology used today.
“We look forward to continued collaboration with Unifrax on FlexCat,” said Wolfram Stichert, CEO, hte GmbH. “We’ve already seen promising results from our testing, and we can’t wait to see what’s ahead for this exciting and brand-new technology.”
Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. To learn more about FlexCat, visit www.unifrax.com/flexcat.
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn and Facebook.
About hte GmbH
At hte – the high throughput experimentation company, we make R&D in the area of catalysis faster and more productive. We enable cost-effective innovations and reduced time-to-market for new products, thereby allowing our customers in the energy & refining, chemical & petrochemical, and environmental industries to keep ahead of the competition. Our technology and services comprise:
- R&D Solutions: highly efficient contract research programs at hte’s state-of-the-art laboratories in Heidelberg, Germany.
- Technology Solutions: integrated hardware and software solutions, enabling our customers to establish high throughput workflows in their own laboratories.
Our customers benefit from broad technical and scientific expertise, exceptional customer orientation, complete end-to-end solutions, and outstanding data quality. Our close ties with BASF guarantee long-term orientation and stability.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005241/en/
Contact information
For Unifrax:
Deborah L. Myers
Global Marketing Communication Director
dmyers@unifrax.com
716.812.4802
For hte GmbH:
Jacqueline Stalica
Marketing Communications Manager
jacqueline.stalica@hte-company.de
+49 (0) 6221 - 74 97 - 290
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 13:00:00 EET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 12:40:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss on intangible assets to income from operations was
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 12:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding to 30 by the end of 2026 Introduction of NIQ’s exclusive EQ2 metric, multiplying units by number in pack to reflect true consumption “The pace of
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 09:47:00 EET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
